Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting

Andrea Zanichelli, Hilary J Longhurst, Marcus Maurer, Laurence Bouillet, Werner Aberer, Vincent Fabien, Irmgard Andresen, Teresa Caballero, IOS Study Group, Anette Bygum (Medlem af forfattergruppering)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

195 Downloads (Pure)

Abstrakt

BACKGROUND: Hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) causes swelling in the skin and upper airways and pain in the abdomen because of mucosal swelling. C1-INH-HAE is frequently misdiagnosed, leading to delays in diagnosis, inadequate treatment, and unnecessary procedures.

OBJECTIVE: To evaluate the history of misdiagnosis in patients participating in the Icatibant Outcome Survey (IOS).

METHODS: The IOS is an observational study in which safety and effectiveness of icatibant have been evaluated since 2009. As part of the IOS, patients record any misdiagnoses received before being diagnosed as having C1-INH-HAE.

RESULTS: In January 2016, a total of 418 of 633 IOS patients with C1-INH-HAE type I or II had provided misdiagnosis data. Of these, 185 of 418 (44.3%) received 1 or more prior misdiagnoses. The most common misdiagnoses were allergic angioedema (103 of 185) and appendicitis (50 of 185). A variety of other misdiagnoses were reported, including a substantial number of gastrointestinal disorders (excluding appendicitis). Misdiagnosis rates were similar between males (41.1%) and females (46.5%) and between C1-INH-HAE type I (43.7%) and type II (51.6%). Patients with family members diagnosed as having C1-INH-HAE were significantly less likely to be misdiagnosed than patients without a family history (140 of 366 [41.7%] vs 38 of 58 [65.5%], respectively; P = .001). Patients with a prior misdiagnosis had longer median delay to C1-INH-HAE diagnosis (13.3 years) than patients without (1.7 years; P < .001).

CONCLUSION: From this large database, approximately 50% of patients with C1-INH-HAE type I or II have previously had their conditions misdiagnosed, most commonly as allergic angioedema or appendicitis. Misdiagnosis results in marked delays in receiving the correct diagnosis, during which time patients cannot access effective, lifesaving treatment.

TRIAL REGISTRATION: ClinicalTrials.gov: NCT01034969.

OriginalsprogEngelsk
TidsskriftAnnals of Allergy, Asthma, & Immunology
Vol/bind117
Udgave nummer4
Sider (fra-til)394-398
ISSN1081-1206
DOI
StatusUdgivet - 1. okt. 2016

Fingeraftryk Dyk ned i forskningsemnerne om 'Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting'. Sammen danner de et unikt fingeraftryk.

  • Citationsformater

    Zanichelli, A., Longhurst, H. J., Maurer, M., Bouillet, L., Aberer, W., Fabien, V., Andresen, I., Caballero, T., IOS Study Group, & Bygum, A. (2016). Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting. Annals of Allergy, Asthma, & Immunology, 117(4), 394-398. https://doi.org/10.1016/j.anai.2016.08.014